2020
DOI: 10.1038/s41436-020-0840-3
|View full text |Cite
|
Sign up to set email alerts
|

Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness

Abstract: Purpose: Several hundred genetic muscle diseases have been described, all of which are rare. Their clinical and genetic heterogeneity means that a genetic diagnosis is challenging. We established an international consortium, MYO-SEQ, to aid the work-ups of muscle disease patients and to better understand disease etiology. Methods: Exome sequencing was applied to 1001 undiagnosed patients recruited from more than 40 neuromuscular disease referral centers; standardized phenotypic information was collected for ea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
57
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 64 publications
(61 citation statements)
references
References 44 publications
(55 reference statements)
3
57
1
Order By: Relevance
“…All families characterized in this study were consanguineous and showed a recessive inheritance pattern. Three individuals (family A, B and C) were included in the MYO–SEQ project [ 11 ]. For these patients, whole exome sequencing (WES) was performed at the Broad Institute’s Genomics Platform, using Illumina exome capture on a cohort of >1800 patients with limb-girdle muscle weakness.…”
Section: Methodsmentioning
confidence: 99%
“…All families characterized in this study were consanguineous and showed a recessive inheritance pattern. Three individuals (family A, B and C) were included in the MYO–SEQ project [ 11 ]. For these patients, whole exome sequencing (WES) was performed at the Broad Institute’s Genomics Platform, using Illumina exome capture on a cohort of >1800 patients with limb-girdle muscle weakness.…”
Section: Methodsmentioning
confidence: 99%
“…For patient 1, we performed a targeted next‐generation sequencing panel for metabolic myopathies, and for other patients, whole‐exome sequencing was recommended. For patients 3, 5 and 6, whole‐exome sequencing analysis was conducted through the MYO‐SEQ project [8]). The MYO‐SEQ project is an international research collaboration that applied targeted whole‐exome sequencing to approximately 1000 patients with undiagnosed proximal muscle weakness [8].…”
Section: Methodsmentioning
confidence: 99%
“…Exome sequencing was carried out on DNA extracted from blood in the framework of the MYO‐SEQ project (Töpf et al, 2020) by focusing on potential mutations in a list of selected 169 genes that are known to be associated with manifestation of neuromuscular disorders (list is available on request). This analysis revealed a homozygous mutation in exon 8 of the FLNC gene (hg19: chr7:128478771C>G; c.1325C>G; p.Pro442Arg) that would lead to exclusive expression of FLNC with a p.Pro442Arg substitution in Ig‐like domain 2 of the FLNC rod domain.…”
Section: Resultsmentioning
confidence: 99%
“…Exome sequencing and data analysis was performed as part of the MYO‐SEQ project (Töpf et al, 2020). Sanger sequencing was performed in DNA to confirm the detected variants.…”
Section: Patients Materials and Methodsmentioning
confidence: 99%